Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below.
Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel’s University City Campus
Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced plans to invest an initial $575M in the creation of a new, state-of-the-art gene therapy innovation center on Drexel University’s campus in the heart of Philadelphia’s University City neighborhood.
Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates
Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates – In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity [….]
Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium
Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation. The data were presented today during the 2021 San Antonio Breast Cancer Symposium (SABCS).
Life Sciences PA today announced its headquarters will be moving from its current location on Swedesford Rd. in Wayne to 411 Swedeland Road in King of Prussia, PA. The
expanded space and rising hub of life sciences in southeastern PA will be the Association’s new home
beginning February 2022.
Carisma Therapeutics Announces Collaboration with Merck to Evaluate CAR-Macrophages in Combination with KEYTRUDA® (pembrolizumab) in a Clinical Study
Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has entered into a clinical study collaboration with Merck (known as MSD outside the US and Canada) to evaluate their proprietary targeted chimeric antigen receptor macrophages (CAR-M) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing cancers.
The Horizon report is based on survey responses from more than 500 industry leaders who provide insight into all corners of the industry. The investigation of cell and gene therapies is proving to be a disruptive space that is reshaping biopharma business models. When cell therapies first went into human testing, Walters said the big question on the minds of the scientists was, “will it work?”
NeuExcell Therapeutics, Inc. Signs Lease with The Discovery Labs to Establish Corporate Headquarters in the Philadelphia Region
NeuExcell Therapeutics, Inc., a preclinical gene therapy company focusing on improving the lives of patients suffering from neurodegenerative diseases, today announced the signing of a lease with The Discovery Labs in King of Prussia, PA. This lease sets the stage for NeuExcell to establish their long-term corporate headquarters in the heart of Philadelphia’s Cellicon Valley region and enables the company to build a world-class team tapping into the veteran cell and gene therapy talent in Greater Philadelphia.
Chimeric Antigen Receptor T cell (CAR-T) therapies, such as those developed by Kite Pharma, have revolutionized the approach to treating hematological cancers, but the therapies have limitations due to toxicity concerns. Pennsylvania-based BlueSphere Bio believes its approach through the use of TCR-T cell therapies will provide a more precise treatment option for patients.
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer.